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were processed by a non linear anisotropic filter and LV edges were identified using an 
active contour algorithm, guided by image gradient. End-diastole and end-systole were 
identified based on R wave synchronization and cavity size, respectively. In both meth- 
ods, LV volumes were calculated by the modified Simpson's rule. A commercially avail- 
able automatic image analysis method was utilized for endocardial detection in MRI (Fast 
Cine, Leiden University version 4.0). Manual analysis showed a good correlation with 
MRI volumes (correlation coefficient r= 0.88); using this automatic approach the corraia- 
fion was still good (r = 0.82); however, LV diastolic and systolic volumes were higher for 
MRI (206 ± 96m1. and 148 ± 105 ml ) than for contrast echo assessed both manually (177 
± 88 mL and 108 ± 73, p= <.001) and automatically (179 ± 104m1. and 107 ± 79 ml. , 
p=.<001). In conclusion, automatic endocardisf border delineation is feasible on contrast 
enhanced images. Despite manual detection on contrast images showed a better corre- 
lation with MRI for LV contour analysis, preliminary results show that this method may 
represent a promising approach for automatic LV function assessment. 
4:48 p.m. 
1144MP-130 QuanUtsUve Three-Dimensional Intravaecular 
Ultrasound: Improvements Toward Semi-Automated 
Border Detection Including the Stent Border 
Jouka Di!kstre, Gerhard Koning, Joan C. Tuinenburg, Pranobo V. Oemrawsingh, Johan 
H.C. Reiber, Leiden University Medical Center, Leiden, The Netherlands. 
Background: IntreVascular UltraSound (IVUS) is a catheter-based technique, which 
provides real-time high-resolution images of the entire arterial wall. The technique is 
used often to monitor the stent placement or to visualize in-stent restenosis. Automation 
of the boundary detection of the stent, lumen, and vessel reduces the required analysis 
time and the subjectivity of the manual tracing procedure. The three-dimensional recon- 
struction permits an advanced assessment of the morphology. 
Methods: The (semi-)automated approach is a combination of transversal and longitudi- 
nal contour detection techniques and is based on a model of the vessel and uses knowl- 
edge about the morphologic structures. The stent contour is detected based on the high 
intensity of the stent struts as compared to other structures and their expected location in 
the vessel wall based on an approximately cimuiar model. The detection method itself is 
able to perform corrections based a continuously three-dimensional structure. 
Results: In a set of 150 slices from different pullback sedas (acquired with Boston Scien- 
tific and EndoSonics equipment) the automatically detected stent boundaries were com- 
pared to manually drawn stent boundaries. The comparison of the cross-sectional stent 
areas for the manually traced and automatically detected boundadss resulted in an r- 
value of 0.99. In a set of 50 pullback runs (acquired with Endosonica equipment) the 
entire stented segment was analyzed automatically and the most distal and the most 
proximal slice in a continuous series of slices containing stent struts was selected to 
assess the stent length. The companson of these distances with the original stent lengths 
resulted in an average overestimation of 0.35 +/- 1.42 mm by IVUS. The start and end 
point of a stent is not well defined because the catheter moves in and out the stent, due 
to cardiac motion. 
Conclusion: Due to the flexible use of more than two longitudinal cutpianes and the 
advanced knowledge-guided contour detection approech, the new IVUS analysis system 
has proven to be suitable for clinical research studies. The inclusion of the stant bound- 
ary is very useful for stent studies e.g. to study the effect of drug coated stents. 
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411-1 A Prospective, Bl inded DeterminaUon of the Natural 
History of Aspir in Resistance Among Stable Cardiac 
Patients 
Patricia A. Gum. Kandica Kottke-Marchant, Eric J. Topoi, The C/eve/and C/inic 
Foundation, C/eveiand, Ohio. 
Background. Aspirin resistance, as defined by comprehensive, ax vivo piatalet function 
testing as well as presumed clinical unresponsiveness to aspirin, has been previously 
reported by our group and others. However, little information exists linking the laboratory 
documentation of aspirin resistance and long-term clinical events. 
Methods. We prospectively enrolled 326 stable cardiac patients from 1997 to 1999 on 
aspidn (325 mg/day for > 7 days) and no other antiplatalst agents. We tested them for 
aspidn sensitivity by optical piatelat aggregation using adenosine diphosphata (ADP) and 
arachidonic acid (AA) and followed them for clinical events. The primary outcome was 
the composite of death, myocardial infarction (MI), or carebrovascuiar accident (CVA). 
Mean follow-up was 679 ± 185 days. Aspirin resistance was defined as a mean aggrega- 
tion of > 70% with 10 p. M ADP and _> 20% with 0.5 rag/ml hA. 
Results. Of the patients studied, 17 (5.2%) were aspirin resistant and 309 (94.8%) were 
not aspirin resistant. Dudng long-term follow-up, aspirin resistance was associated with a 
significantly increased risk of death, MI, or CVA compared to patients who were aspidn 
sensitive (24% vs 10%, HR 3.12, 95% CI (1.10-8.90), p=0.03). Stratified multivadata 
analyses identified elevated piatelet count, advancing age, history of congestive heart 
failure and aspirin resistance to be independently associated with major adverse long- 
term outcomes (HR for aspirin resistance 4.14, 95% CI (1.42-12.06), p=0.009). 
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Conclusion. This study is the first prospective determinant of the natural history of aspi- 
rin resistance, documenting a greater than 2-fold increase in the risk of major adverse 
events associated with aspirin resistance. 
4:15 p.m. 
411-2 Loss of Thrombomodulin Expression Impairs Vein Graft 
Thromboreslstance 
Antony Y. Kim. Kenneth Lee Baughman, Peter L. Walinsky, Frank D. Kolodgie, C. E. 
Bean, Jason Sperry, Clayton Deming, Eric Peck, Jay Shake, Gregory Ang, Chades 
Eamon, Rsnu Virmani, Jeffrey Rada, Johns Hopkins Schoo/ of Medicine, Baltimore, 
Mary~and. 
Background: Thrombosis is the major cause of eady vein graft failure. The aim of this 
study was to determine whether alterations in the expression of the anticoagulant pro- 
teins, thrombomodulin (TM) and the endothelial call protein C receptor (EPCR), impair 
endothelial thromboresistance and contribute to vein graft failure. Methods and 
Results: Immunohistochamical nalysis of autologous rabbit vein grafts revealed that 
the expression of TM, but not EPCR, was reduced by 98% 3 days after implantation, with 
gradual but incomplete recovery by 42 days. This resulted in up to a 95% reduction in the 
capacity of the grafts to activate protein C and was associated with increased bound 
thrombin activity, that peaked on day 7 at 28.7" 3.8 mU/cm 2 and persisted for over 14 
days. Restoration of TM expression using adenovirus vector-mediatad gene transfer sig- 
nificantly enhanced the capacity of grafts to activate protein C and resulted in a near 80% 
reduction in bound thrombin activity on day 7, to levels comparable to normal veins (5.7" 
0.4 vs. 5.2 " 1.1 mU/cm 2, respectively, p= 0.74). Surprisingly, neointima formation was 
not affected by this inhibition of local thrombin generation. Conclusions: These results 
suggest that eady loss of TM expression enhances local thrombin generation that con- 
tributes to early vein graft failure due to thrombosis, but does not contribute significantly 
to late vein graft failure due to neointimal hyperplasia. 
4:30 p.m. 
411-3 Improvement in Diastolic Suction In Patients With 
Hypertrophic Obstructive Cardiomyopathy After Septsl 
Ablation 
Aleksendr Rovner. Marta Sitges, Rebecca Smith, Nell L. Greanborg, Irmian Yiassak, 
Takahiro Shiota, Murat E. Tuzcu, Nicholas Smadira, Harry M. Lever, James D. Thomas, 
Mario J. Garcia, Department of Cardiovascular Medicine, The Clave~and C/inic 
Foundation, C/eve/and, Ohio. 
Background: Saptal alcohol ablation (PTSA) is an effective treatment in hypertrophic 
obstructive cardiomyopathy (HOCM). Intraventricuiar pressure gradient (IVPG) is a novel 
method to evaluate diastolic function. Our aim was to analyze the IVPG and diastolic 
function in HOCM patients with PTSA. 
Methods: 19 patients had an echocardiogram performed at baseline end after PTSA 
(mean follow up 5.6-J:1.2 months). Diastolic parameters were obtained using PW-Doppler 
through the mitral valve (E, A, DT), pulmonary venous flow (S, D), mitral annulus tissue 
Doppler imaging (Ea). Color M-mode was used to obtain the flow propagation velocity 
(Vp) through the mitral valve and to calculate IVPG oft-line using custom written soft- 
ware. LV dimensions were obtained. LV outflow tract (LVOT) gradient was calculated. 
Results: LVOT gradient decreased from 62±10 to 29:t:5 mmHg (p<0.001), severity of 
mitrel regurgitation (MR) decreased from 2.1:L-0.2 to 1.3!-0.2 (p<0.01). The septal size 
decreased from 2.3i~-0.09 to 1.9t0.05 mm (p<0.01). Diastolic results are shown in the 
Table. 
IVPG Vp (era/ E/A DT (ms) S/D EWp E/Ea 
(mmHg) s) 
Pre 1.5t-0.2 48+5 1.5±0.2 258±15 1.2!-0.1 2.2_+0.2 14.?_.-~.5 
Post 2.6+0.3* 74+7* 0.9t-0.1" 256+12 1.3-~0.1 1.3i0.1" 11.3±1.3 
*p<0.01 vs Pre. 
The increase in IVPG correlated with the increase in Vp (r=0.5) and with the decrease in 
LVOT gradient (r=-0.6), F_Np (r=-0.5), E/Ea (r=-0.7), (all p<0.05), and decrease in MR 
(r=-0.7, p<0.01). No correlation was found between the increase in IVPG and decrease in 
E/A, S/D and DT. 
Conclusion: IVPG is a reliable indicator of diastolic function improvement in HOCM after 
PTSA as indicated by the increase in IVPG and change in other diastolic parameters. 
4:45 p.m. 
411-4 L-Arginine Protects Human Heart Cells From Simulated 
Anoxia and Reoxgenation 
Subodh Verma. Noritsugu Shiono, Ran-Ks Li, Donald A. Miokle, Paul W. Fedak, Richard 
D. Waissf, University of Toronto, Toronto, Ontario, Canada. 
The present study was conducted to evaluate the direct affects of L-arginine in a human 
ventricular heart cell model of simulated isohemia and reperfusion independent of alter- 
nate cell types such as endothelial cells, neutrophils, platelets or fibroblasts. Human ven- 
tdcuiar heart call cultures were subjected to 90 minutes of low volume isohemia and 30 
minutes of reperfusion. L-arginina (0-5.0 mM) was administered udng the pre-ischemic 
period or dudng the reperfusion phase. Nitric oxide synthase (NOS) activity, nitric oxide 
(NO) production, cGMP levels and cellular injury were assessed. To evaluate the effects 
of L-arginine on cell signaling, the effects of NOS antagonist (L-NAME), NO donor 
(SNAP), guanylate cyciase inhibitor (methylene blue), cGMP analogue (8-BrCGMP) and 
KAT P antagonist (glibenclamide) were examined. Our data indicate, that ischemia and 
reperfusion increased NOS activity and facilitated the conversion of L-arginine to NO, 
p-  
~./3, 
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wi~ich provided protection against the effects of ischemia and raperfusion in a dose- 
dependent fashion. In addition, L-arginine eardioprotection was mediated by the activa- 
tion of guanyiate cyclaee leading to increased cGMP levels in human heart cells. The 
final effector of NO/cGMP may be the opening of KAT P channels. 
5:00 p.m. 
411-5 L-Arginine for  Partial Reeynchronization of Abnormal  
Peripheral Vascular Reactivity in Heart Failure: A 
Prospective Randomized Double-Blind Study 
Moi~ammed Yousufuddirl, Mohamed Amrani, Waqar Shamim, Faisal AI-Nasser, Fouad 
Amin, Nicholas R. Banner, Andrew J S. Coats, Nationa/Heart and Lung/nstitute, 
London, United Kingdom. 
We investigated the effects of oral I-arginine (ARG) supplement on brachial artery (BA) 
reactivity in patient with CHF. Methods: Fiffy-men (59±10 yr.) with stable CHF of NYHA 
grade I-III and ejection fraction <40% were randomized to oral ARG or matching placebo 
for 1-week. Twenty-healthy men (57±9yr) with no clinical evidence of disease served as 
parallel controls for baseline comparison. BA reactivity was measured as a) flow-medi- 
ated dilation (FMD) in response to hyperemia induced by 5-min of distal forearm occlu- 
sion by blood pressure cuff, b) exercise-induced constriction (EIC) immediately after 
treadmill exemise, and c) resting, hyperemic and post-exeroise BA blood flow by high- 
resolution ultrasound technique using 8-11 MHz vascular probe connected to SONO 
5500 (Agilant Tech, USA). FMD and EIC were measured as % change in diameter of the 
BA after increased flow and exemise respectively. Exercise was performed with modified 
Bruce protocol and peak oxygen consumption (VO2) was measured (AMIS 2000, Den- 
mark). Exhaled nitric oxide (NO) was measured by a chemiluminescence analyzer. 
Investigations were performed after overnight fast under identical condition. Inferential 
statistics were restricted to CHF patients. Results: ARG and placebo patient-groups and 
controls were similar in demographics. Baseline characteristics were comparable 
between ARG and placebo groups in patients. Controls and patients differ in their BA 
reactivity and exercise capacity with former showing higher FMD and VO 2 but lower EIC 
(all P<0.0001). At one-wk FMD (2.24t-0.89 to2.6±1.1 Vs 2.3t0.32 to 2.3+1.07%;P=0.02) 
has increased while EIC (7.2±4.0 to 5.3±2.8 vs 5.9±3.2 to 5.8+3.1%;p=0.02) decreased 
with ARG supplementation compared to placebo in patients. Exhaled NO was increased, 
independent of changes in FMD or EIC in ARG arm compared to placebo (7.6±2.8 to 
9.4+3.4; vs 8.9-~2.5 to 9.4±3.4 parts per billion; P=0.01). Patients, who received ARG 
demonstrated a strong trend toward increase in exercise interval, VO2, and hyperamic 
blood flow compared to placebo group. Conclusion: ARG, via an increase in NO bioavial- 
ability, partially resynchronizes brachial artery reactivity towards normal in patients with 
CHF. 
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An Institutional Discharge Medication Program 
Reduces Future Cardiovascular Readmiselons and 
Mortality: An Analysis of 43,841 Patients With Coronary 
Artery Disease 
Robert R. Pearson. Benjamin D. Home, Chloe A. Allen Maycock, Donald L. Lappe', 
Susan Krelick-Goldberg, Tami L. Bair, Janette A. Orton, Diane S. Wallace, Haeli 
Hanseen, Dale G. Renlund, Joseph B. Muhlestein, LDS Hospital Salt Lake Ci~ Utah. 
Background: Patients (pts) admitted with a diagnosis of coronary artery disease (CAD) 
carry a significant risk of re-hospitalization or death during the year after discharge. We 
have shown that successful implementation of a multi-faceted ischarge medication pro- 
gram (DMP) increases the likelihood of CAD pts being discharged on appropriate medi. 
cal therapy (ASNAntiplatelet and a statin for all; Beta-Blockers post-MI). We 
hypothesized that this DMP would result in reduced cardiovascular eadmissions and 
mortality. 
Methods: We analyzed 43,841 pts discharged after a CAD-related hospitalization from 
10 hospitals within an integrated health care system. Implementation of the DMP was ini- 
tiated in 1/1999 and increased overall medication use from 65% to 95%. We compared 
one year cardiovascular eadmission or death rates of pts discharged between 1/1996- 
12/1998 (n=25,185) (pre-DMP) to pts discharged between 1/1999-6/2000 (n=18,656) 
(post-DMP). 
Results: Average pt age was 64±15 years; 62% were male; demographics did not differ 
between pre- and post-DMP groups. After controlling for age and gender in Cox regres- 
sion, post-DMP one-year re-admission rates were reduced from 20.4% to 17.7% (hazard 
ratio lHR]=0.86, p<0.001) and one-year mortality was reduced from 4.5% to 3.5% 
(HR--0.79, p<0.001). 
Conclusions: The successful implementation of an institutional cardiac DMP can signifi- 
cantly lower the rate at which pts with CAD are rsadmitted for cardiac complications and 
also will lower their mortality rates. 
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849-2 Quality of Care of Patients Admitted With Congeative 
Heart Failure: Influence of Physician Specialty end 
Hospital Type 
Jay K. Amin. Michael J. Lim, Yassar Almanaseer, Chih-Wen Pal, Gerdann Finnegen, Kim 
A. Eagle, Rajendre H. Mehta, University of Michigan, Ann Arbor, Michigan, Michigan 
Peer Review Organization, Plymouth, Michigan. 
Background: Congestive heart failure (CHF) is a common admission diagnosis in eld- 
edy patients (pts) in the United States. Increased resource utilization by CHF pts has 
generated great interest in improving quality of care for these pts. The impact of physi- 
cian specialty and hospital type on the quality of care has not been well studied. 
Methods: We evaluated 5871 Medicare beneficiadas admitted to 31 acute care hospitals 
in Southeast Michigan with CHF (1/98-12/98). Patients were identified retrospectively 
using ICD-9 codes for CHF. Indicators were evaluated with respect to physician specialty 
(cardiologist vs. non-cardiologist) and hospital type (teaching, n=17 vs. non-taaching, 
n=14). 
Results: Indicators are shown (Table). Patients treated by cardiologists had shorter 
length of stay (LOS, 5.5 vs. 6.0 days, p<.001) and similar 1-year mortality rates (37.9% 
vs. 35%, p=.06) compared to non-cardiologists. Patients treated in teaching hospitals 
had shorter LOS (5.6 vs. 6.1 days, p<.001) and lower 1-year mortality rates (34.7% vs. 
37.4%, p=.04). 
Conclusion: Quality of care for CHF pts tends to be less optimal in those treated by non- 
cardiologists and at non-teaching hospitals despite similar or higher mortality rates. This 
data supports the need for further educating non-cardiologists in the management of eld- 
erly pts admitted with CHF. In addition, it suggests that systemization of processes at 
non-teaching hospitals may improve the quality of care for CHF pts, thus leading to petter 
long-term outcomes. 
Quality Indicators Teaching Non- PValue Cardiologist, Non- PValue 
Hospital, teaching n=1297 cardiologist, 
n=3350 Hospital, n=3599 
n=2521 
Discharge ACE-inhibitor/ARB 81.6 73 <0.001 79.6 76.5 0.24 
(%) 
LVEF documented (%) 70.5 64.6 <0.001 65.3 68.3 0.05 
Discharge smoking cessation 24.0 34.5 0.08 28.1 27.9 0.98 
counseling (%) 
Discharge written instructions 97.0 97.3 0.75 97.8 97 0.43 
(%) 
Weights measured, >50% 68.4 61.6 0.006 77.7 62.6 <0.001 
hospital days (%) 
Discharge warfarin in CHF pts 48.7 41.7 0.16 56.5 39.1 <0.001 
with atrial fibrillation (%) 
9:00 a.m. 
849-3 Regional Differences in Quality of Care for Heart 
Failure: The Role of Patient, Physician, and Hospltsl 
Characteristics 
Edward P. Havranek, Pare Wolfe, Frededck A. Masoudi, Hadan M. Krumholz, Saif S. 
Rathore, Beth Stevens, Diana L. Ordin, Colorado Foundation for Medical Care, Aurora, 
Colorado. 
Background: Quality of care for eldedy heart failure patients varies across the United 
States, but the extent to which patient, provider and hospital charecteristics contribute to 
this vadation is unknown. Methods: We used data from the National Heart Failure 
project, a Center for Medicare and Medicaid Services quality initiative that studied 37,500 
Medicare patients hospitalized with heart failure, to evaluate the extent to which patient, 
physician and hospital characteristics explain regional vadation in heart failure treatment. 
Small area variation for two quality indicators (QI)- documentation of ejection fraction 
(EF) and appropriate prescription of angiotansin converting enzyme inhibitor (ACEI)- was 
assessed by estimating the Ol rates by Hospitat Referral Regions (HRRs) in the United 
States using a non-linear mixed-effects model To identify variables associated with per- 
formance on the quality indicators by census divisions we used the method of general- 
ized estimating equations for a logistic model entenng HRR as a random effect. We 
compared the distribution of the predictors across regions using a chi-squara test for 
